Search research articles
Contact Us
Filters
Showing results (361-370 of 387) with videos related to
Page
of 39
Sort By:
The New England Journal of Medicine
|
October 4, 2016
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Eric L Simpson, Thomas Bieber, Emma Guttman-Yassky, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
June 30, 2026
Assessment and Clinical Management of Patients With Atopic Dermatitis Undergoing Patch Testing: Recommendations From an International Electronic Delphi Consensus
Jamie P Schlarbaum, Erin M Warshaw, Yael A Leshem, et al.
Allergy
|
July 22, 2020
Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines
Ioana Agache, Yang Song, Margarita Posso, et al.
Nature
|
February 25, 2026
Peripheral immune-inducer dendritic cells drive early-life allergic inflammation
Yue Xing, Ilana Reznikov, Abonti Nur Ahmed, et al.
The Journal of Allergy and Clinical Immunology
|
June 10, 2021
Polygenic prediction of atopic dermatitis improves with atopic training and filaggrin factors
Christopher H Arehart, Michelle Daya, Monica Campbell, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
January 10, 2025
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial
Eric L Simpson, Lawrence F Eichenfield, Kim A Papp, et al.
American Journal of Clinical Dermatology
|
September 3, 2025
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks
Alan D Irvine, Vimal H Prajapati, Emma Guttman-Yassky, et al.
Allergy
|
August 9, 2020
Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines
Ioana Agache, Claudio Rocha, Ana Pereira, et al.
The Journal of Experimental Medicine
|
July 19, 2021
Single-cell analysis of human skin identifies CD14+ type 3 dendritic cells co-producing IL1B and IL23A in psoriasis
Satoshi Nakamizo, Charles-Antoine Dutertre, Ahad Khalilnezhad, et al.
JAMA Dermatology
|
November 7, 2019
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial
Eric L Simpson, Amy S Paller, Elaine C Siegfried, et al.
Page
of 39
Search research articles
Search
Showing results (361-370 of 387) with videos related to
Sort By:
Page
of 39
The New England Journal of Medicine
|
October 4, 2016
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Eric L Simpson, Thomas Bieber, Emma Guttman-Yassky, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
June 30, 2026
Assessment and Clinical Management of Patients With Atopic Dermatitis Undergoing Patch Testing: Recommendations From an International Electronic Delphi Consensus
Jamie P Schlarbaum, Erin M Warshaw, Yael A Leshem, et al.
Allergy
|
July 22, 2020
Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines
Ioana Agache, Yang Song, Margarita Posso, et al.
Nature
|
February 25, 2026
Peripheral immune-inducer dendritic cells drive early-life allergic inflammation
Yue Xing, Ilana Reznikov, Abonti Nur Ahmed, et al.
The Journal of Allergy and Clinical Immunology
|
June 10, 2021
Polygenic prediction of atopic dermatitis improves with atopic training and filaggrin factors
Christopher H Arehart, Michelle Daya, Monica Campbell, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
January 10, 2025
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial
Eric L Simpson, Lawrence F Eichenfield, Kim A Papp, et al.
American Journal of Clinical Dermatology
|
September 3, 2025
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks
Alan D Irvine, Vimal H Prajapati, Emma Guttman-Yassky, et al.
Allergy
|
August 9, 2020
Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines
Ioana Agache, Claudio Rocha, Ana Pereira, et al.
The Journal of Experimental Medicine
|
July 19, 2021
Single-cell analysis of human skin identifies CD14+ type 3 dendritic cells co-producing IL1B and IL23A in psoriasis
Satoshi Nakamizo, Charles-Antoine Dutertre, Ahad Khalilnezhad, et al.
JAMA Dermatology
|
November 7, 2019
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial
Eric L Simpson, Amy S Paller, Elaine C Siegfried, et al.
Page
of 39